Expertise in
3
conditions

Kristina Lindemann

Oslo, NO 
Expertise in
3
conditions
Oslo, NO 

Overview

Kristina Lindemann practices practicing medicine in Oslo, Norway.

Ms. Lindemann is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Cerebral Hypoxia, and Salpingo-Oophorectomy.

She is actively involved in clinical research, co-authoring 104 peer reviewed articles and participating in 5 clinical trials.

Gender

Female

Locations

Oslo, Norway
Other Locations
Nydalen, 0424, Norway
Blindern, 0318, Norway
1478, Norway

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Enrollment Status: Completed
Publish Date: April 21, 2026
Intervention Type: Drug
Study Drugs: Bevacizumab, Cisplatin, Carboplatin, Paclitaxel, Atezolizumab
Study Phase: Phase 3
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Dostarlimab, Carboplatin, Paclitaxel, Niraparib
Study Phase: Phase 3
NSGO-OV-UMB1; ENGOT-OV30 / NSGO: A Phase II Umbrella Trial in Patients With Relapsed Ovarian Cancer
NSGO-OV-UMB1; ENGOT-OV30 / NSGO: A Phase II Umbrella Trial in Patients With Relapsed Ovarian Cancer
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug
Study Drugs: Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562
Study Phase: Phase 2
Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial
Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug
Study Drugs: Bevacizumab, Atezolizumab, Chemotherapy
Study Phase: Phase 3
View 4 Less Clinical Trials

104 Total Publications

Pragmatic gynecologic cancer clinical trials: statements and roadmap from the Gynecologic Cancer InterGroup Chicago Brainstorming Meeting.
Pragmatic gynecologic cancer clinical trials: statements and roadmap from the Gynecologic Cancer InterGroup Chicago Brainstorming Meeting.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: June 13, 2026

Frequently Asked Questions about Kristina Lindemann

Is Kristina Lindemann a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Kristina Lindemann is classified as an Elite expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Kristina Lindemann participate in research or clinical trials?

Yes. Kristina Lindemann has published 104 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Kristina Lindemann's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Lindemann's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile